Annual CFF
-$10.86 M
-$12.55 M-740.91%
31 December 2023
Summary:
Catalyst Pharmaceuticals annual cash flow from financing activities is currently -$10.86 million, with the most recent change of -$12.55 million (-740.91%) on 31 December 2023. During the last 3 years, it has fallen by -$11.56 million (-1646.58%). CPRX annual CFF is now -118.93% below its all-time high of $57.35 million, reached on 31 December 2017.CPRX Cash From Financing Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly CFF
-$5.97 M
-$7.13 M-616.34%
30 September 2024
Summary:
Catalyst Pharmaceuticals quarterly cash flow from financing activities is currently -$5.97 million, with the most recent change of -$7.13 million (-616.34%) on 30 September 2024. Over the past year, it has increased by +$4.15 million (+41.01%). CPRX quarterly CFF is now -104.24% below its all-time high of $141.05 million, reached on 31 March 2024.CPRX Quarterly CFF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM CFF
$135.57 M
+$4.15 M+3.16%
30 September 2024
Summary:
Catalyst Pharmaceuticals TTM cash flow from financing activities is currently $135.57 million, with the most recent change of +$4.15 million (+3.16%) on 30 September 2024. Over the past year, it has increased by +$143.51 million (+1807.61%). CPRX TTM CFF is now at all-time high.CPRX TTM CFF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
CPRX Cash From Financing Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -740.9% | +41.0% | +1807.6% |
| 3 y3 years | -1646.6% | -184.8% | +2524.7% |
| 5 y5 years | -3804.2% | -2432.7% | +10000.0% |
CPRX Cash From Financing High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | -740.9% | at low | -104.2% | +41.0% | at high | +1348.7% |
| 5 y | 5 years | -740.9% | at low | -104.2% | +41.0% | at high | +1348.7% |
| alltime | all time | -118.9% | at low | -104.2% | +41.0% | at high | +1348.7% |
Catalyst Pharmaceuticals Cash From Financing History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | -$5.97 M(-616.3%) | $135.57 M(+3.2%) |
| June 2024 | - | $1.16 M(-99.2%) | $131.41 M(+1.1%) |
| Mar 2024 | - | $141.05 M(<-9900.0%) | $130.04 M(-1297.8%) |
| Dec 2023 | -$10.86 M(-740.9%) | -$665.00 K(-93.4%) | -$10.86 M(+36.8%) |
| Sept 2023 | - | -$10.13 M(+4632.2%) | -$7.94 M(-228.6%) |
| June 2023 | - | -$214.00 K(-243.6%) | $6.17 M(+81.9%) |
| Mar 2023 | - | $149.00 K(-93.4%) | $3.39 M(+100.4%) |
| Dec 2022 | $1.69 M(-120.8%) | $2.25 M(-43.4%) | $1.69 M(-154.9%) |
| Sept 2022 | - | $3.98 M(-233.2%) | -$3.08 M(-66.3%) |
| June 2022 | - | -$2.99 M(+92.9%) | -$9.17 M(-7.2%) |
| Mar 2022 | - | -$1.55 M(-38.6%) | -$9.88 M(+21.4%) |
| Dec 2021 | -$8.14 M(-1260.0%) | -$2.53 M(+20.4%) | -$8.14 M(+45.6%) |
| Sept 2021 | - | -$2.10 M(-43.4%) | -$5.59 M(+94.2%) |
| June 2021 | - | -$3.71 M(-2071.8%) | -$2.88 M(-433.2%) |
| Mar 2021 | - | $188.00 K(+623.1%) | $864.00 K(+23.1%) |
| Dec 2020 | $702.00 K(-37.1%) | $26.00 K(-95.8%) | $702.00 K(-44.0%) |
| Sept 2020 | - | $614.00 K(+1605.6%) | $1.25 M(+39.9%) |
| June 2020 | - | $36.00 K(+38.5%) | $896.10 K(-14.9%) |
| Mar 2020 | - | $26.00 K(-95.5%) | $1.05 M(-5.7%) |
| Dec 2019 | $1.12 M(+280.8%) | $578.00 K(+125.7%) | $1.12 M(+61.9%) |
| Sept 2019 | - | $256.10 K(+33.0%) | $689.40 K(+28.2%) |
| June 2019 | - | $192.50 K(+115.6%) | $537.80 K(+53.9%) |
| Mar 2019 | - | $89.30 K(-41.1%) | $349.40 K(+19.2%) |
| Dec 2018 | $293.10 K(-99.5%) | $151.50 K(+45.0%) | $293.10 K(-99.5%) |
| Sept 2018 | - | $104.50 K(+2448.8%) | $54.28 M(-2.3%) |
| June 2018 | - | $4100.00(-87.6%) | $55.58 M(-3.1%) |
| Mar 2018 | - | $33.00 K(-99.9%) | $57.38 M(+0.1%) |
| Dec 2017 | $57.35 M(>+9900.0%) | $54.14 M(+3745.2%) | $57.35 M(+1641.3%) |
| Sept 2017 | - | $1.41 M(-22.0%) | $3.29 M(+74.7%) |
| June 2017 | - | $1.81 M(>+9900.0%) | $1.89 M(+2248.3%) |
| Mar 2017 | - | $0.00(-100.0%) | $80.30 K(+16.4%) |
| Dec 2016 | $69.00 K(-99.8%) | $80.30 K(>+9900.0%) | $69.00 K(+27.5%) |
| Sept 2016 | - | $0.00(0.0%) | $54.10 K(-94.4%) |
| June 2016 | - | $0.00(-100.0%) | $970.70 K(-10.4%) |
| Mar 2016 | - | -$11.30 K(-117.3%) | $1.08 M(-97.1%) |
| Dec 2015 | $37.16 M | $65.40 K(-92.9%) | $37.16 M(-4.5%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2015 | - | $916.60 K(+711.2%) | $38.92 M(+2.4%) |
| June 2015 | - | $113.00 K(-99.7%) | $38.00 M(-41.2%) |
| Mar 2015 | - | $36.06 M(+1879.4%) | $64.61 M(+126.2%) |
| Dec 2014 | $28.56 M(+57.1%) | $1.82 M(>+9900.0%) | $28.56 M(+6.1%) |
| Sept 2014 | - | $0.00(-100.0%) | $26.93 M(-40.0%) |
| June 2014 | - | $26.73 M(>+9900.0%) | $44.90 M(+146.8%) |
| Mar 2014 | - | $16.50 K(-91.3%) | $18.20 M(+0.1%) |
| Dec 2013 | $18.18 M(+24.7%) | $189.80 K(-98.9%) | $18.18 M(-21.2%) |
| Sept 2013 | - | $17.97 M(>+9900.0%) | $23.07 M(+116.3%) |
| June 2013 | - | $23.50 K(>+9900.0%) | $10.67 M(-26.8%) |
| Mar 2013 | - | $0.00(-100.0%) | $14.58 M(0.0%) |
| Dec 2012 | $14.58 M(+163.1%) | $5.08 M(-8.6%) | $14.58 M(+13.8%) |
| Sept 2012 | - | $5.56 M(+41.2%) | $12.81 M(+76.7%) |
| June 2012 | - | $3.94 M(>+9900.0%) | $7.25 M(+118.8%) |
| Mar 2012 | - | $0.00(-100.0%) | $3.31 M(-40.2%) |
| Dec 2011 | $5.54 M(+280.6%) | $3.31 M(>+9900.0%) | $5.54 M(+148.7%) |
| Sept 2011 | - | $0.00(0.0%) | $2.23 M(-39.5%) |
| June 2011 | - | $0.00(-100.0%) | $3.68 M(0.0%) |
| Mar 2011 | - | $2.23 M(>+9900.0%) | $3.68 M(+153.0%) |
| Dec 2010 | $1.46 M(-60.6%) | $0.00(-100.0%) | $1.46 M(-71.7%) |
| Sept 2010 | - | $1.46 M(>+9900.0%) | $5.15 M(+39.4%) |
| June 2010 | - | $0.00(0.0%) | $3.70 M(0.0%) |
| Mar 2010 | - | $0.00(-100.0%) | $3.70 M(0.0%) |
| Dec 2009 | $3.70 M(-9.5%) | $3.70 M(>+9900.0%) | $3.70 M(-1127.0%) |
| Sept 2009 | - | $0.00(-100.0%) | -$360.10 K(-108.8%) |
| Dec 2008 | $4.08 M(>+9900.0%) | -$360.10 K(-108.1%) | $4.08 M(-8.1%) |
| Sept 2008 | - | $4.46 M(<-9900.0%) | $4.44 M(<-9900.0%) |
| June 2008 | - | -$17.00 K(+750.0%) | -$19.00 K(+850.0%) |
| Mar 2008 | - | -$2000.00(<-9900.0%) | -$2000.00(<-9900.0%) |
| Dec 2007 | $0.00(-100.0%) | $0.00(0.0%) | $0.00(0.0%) |
| Sept 2007 | - | $0.00(0.0%) | $0.00(0.0%) |
| June 2007 | - | $0.00(0.0%) | $0.00(0.0%) |
| Mar 2007 | - | $0.00 | $0.00 |
| Dec 2006 | $20.86 M(+1893.6%) | - | - |
| Dec 2005 | $1.05 M(>+9900.0%) | - | - |
| Dec 2004 | $0.00 | - | - |
FAQ
- What is Catalyst Pharmaceuticals annual cash flow from financing activities?
- What is the all time high annual CFF for Catalyst Pharmaceuticals?
- What is Catalyst Pharmaceuticals annual CFF year-on-year change?
- What is Catalyst Pharmaceuticals quarterly cash flow from financing activities?
- What is the all time high quarterly CFF for Catalyst Pharmaceuticals?
- What is Catalyst Pharmaceuticals quarterly CFF year-on-year change?
- What is Catalyst Pharmaceuticals TTM cash flow from financing activities?
- What is the all time high TTM CFF for Catalyst Pharmaceuticals?
- What is Catalyst Pharmaceuticals TTM CFF year-on-year change?
What is Catalyst Pharmaceuticals annual cash flow from financing activities?
The current annual CFF of CPRX is -$10.86 M
What is the all time high annual CFF for Catalyst Pharmaceuticals?
Catalyst Pharmaceuticals all-time high annual cash flow from financing activities is $57.35 M
What is Catalyst Pharmaceuticals annual CFF year-on-year change?
Over the past year, CPRX annual cash flow from financing activities has changed by -$12.55 M (-740.91%)
What is Catalyst Pharmaceuticals quarterly cash flow from financing activities?
The current quarterly CFF of CPRX is -$5.97 M
What is the all time high quarterly CFF for Catalyst Pharmaceuticals?
Catalyst Pharmaceuticals all-time high quarterly cash flow from financing activities is $141.05 M
What is Catalyst Pharmaceuticals quarterly CFF year-on-year change?
Over the past year, CPRX quarterly cash flow from financing activities has changed by +$4.15 M (+41.01%)
What is Catalyst Pharmaceuticals TTM cash flow from financing activities?
The current TTM CFF of CPRX is $135.57 M
What is the all time high TTM CFF for Catalyst Pharmaceuticals?
Catalyst Pharmaceuticals all-time high TTM cash flow from financing activities is $135.57 M
What is Catalyst Pharmaceuticals TTM CFF year-on-year change?
Over the past year, CPRX TTM cash flow from financing activities has changed by +$143.51 M (+1807.61%)